Abstract：
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020. Since then, there has been an urgent need for effective therapeutic methods to manage the disease. We aimed to assess the effectiveness of molnupiravir in reducing the need for hospitalization in at-risk, non-hospitalized COVID-19 patients.
METHODS: This was a single-center, non-randomized, observational retrospective study of non-hospitalized patients with confirmed COVID-19, treated at the Clinic for Infectious and Tropical Diseases, University Clinical Center in Belgrade, Serbia.
RESULTS: The study was conducted between 15 December 2021 and 15 February 2022 and included 320 patients. Of these, 165 (51.6%) received treatment with molnupiravir. The study and control groups were similar in gender and age distribution. The study group had a higher proportion of vaccination (75.2% vs. 51%, p < 0.001). There was no statistically significant difference in presence of comorbidity within the groups. Majority of the patients who received molnupiravir did not require hospitalization; and this was statistically significant in comparison to control group (92.7 vs. 24.5%, p < 0.001). Oxygen supplementation was less frequently required in the study group compared to the control group (0.6% vs. 31%, p < 0.001). During the follow-up period of 12.12 ± 3.5 days, significantly less patients from the study group were admitted to the intensive care unit (p < 0.001). Molnupiravir significantly reduced the risk of hospitalization by 97.9% (HR 0.021; 95% CI 0.005-0.089; p < 0.001).
CONCLUSIONS: Molnupiravir is an effective therapy in preventing the development of severe forms of COVID-19 and hospitalization.
METHODS: This was a single-center, non-randomized, observational retrospective study of non-hospitalized patients with confirmed COVID-19, treated at the Clinic for Infectious and Tropical Diseases, University Clinical Center in Belgrade, Serbia.
RESULTS: The study was conducted between 15 December 2021 and 15 February 2022 and included 320 patients. Of these, 165 (51.6%) received treatment with molnupiravir. The study and control groups were similar in gender and age distribution. The study group had a higher proportion of vaccination (75.2% vs. 51%, p < 0.001). There was no statistically significant difference in presence of comorbidity within the groups. Majority of the patients who received molnupiravir did not require hospitalization; and this was statistically significant in comparison to control group (92.7 vs. 24.5%, p < 0.001). Oxygen supplementation was less frequently required in the study group compared to the control group (0.6% vs. 31%, p < 0.001). During the follow-up period of 12.12 ± 3.5 days, significantly less patients from the study group were admitted to the intensive care unit (p < 0.001). Molnupiravir significantly reduced the risk of hospitalization by 97.9% (HR 0.021; 95% CI 0.005-0.089; p < 0.001).
CONCLUSIONS: Molnupiravir is an effective therapy in preventing the development of severe forms of COVID-19 and hospitalization.
摘要：
背景：2019年冠状病毒病（COVID-19）大流行始于2020年3月。从那以后,迫切需要有效的治疗方法来控制该疾病。我们的目的是评估莫那普拉韦在减少高危人群住院需求方面的有效性，非住院COVID-19患者。
方法：这是一个单中心，非随机化，在传染病和热带病诊所接受治疗的非住院确诊COVID-19患者的观察性回顾性研究，贝尔格莱德大学临床中心，塞尔维亚。
结果：该研究于2021年12月15日至2022年2月15日进行，包括320名患者。其中,165人（51.6％）接受了莫努普拉韦治疗。研究组和对照组在性别和年龄分布上相似。研究组的疫苗接种比例更高(75.2%vs.51%,p<0.001)。组内合并症的存在没有统计学上的显著差异。接受molnupiravir的大多数患者不需要住院治疗；与对照组相比，这在统计学上是显著的(92.7vs.24.5%,p<0.001)。与对照组相比，研究组需要补充氧气的频率较低（0.6％vs.31%,p<0.001)。随访12.12±3.5天,研究组入住重症监护病房的患者明显较少(p<0.001).Molnupiravir可显著降低住院风险达97.9%(HR0.021;95%CI0.005-0.089;p<0.001)。
结论：Molnupiravir是预防严重COVID-19和住院的有效疗法。
方法：这是一个单中心，非随机化，在传染病和热带病诊所接受治疗的非住院确诊COVID-19患者的观察性回顾性研究，贝尔格莱德大学临床中心，塞尔维亚。
结果：该研究于2021年12月15日至2022年2月15日进行，包括320名患者。其中,165人（51.6％）接受了莫努普拉韦治疗。研究组和对照组在性别和年龄分布上相似。研究组的疫苗接种比例更高(75.2%vs.51%,p<0.001)。组内合并症的存在没有统计学上的显著差异。接受molnupiravir的大多数患者不需要住院治疗；与对照组相比，这在统计学上是显著的(92.7vs.24.5%,p<0.001)。与对照组相比，研究组需要补充氧气的频率较低（0.6％vs.31%,p<0.001)。随访12.12±3.5天,研究组入住重症监护病房的患者明显较少(p<0.001).Molnupiravir可显著降低住院风险达97.9%(HR0.021;95%CI0.005-0.089;p<0.001)。
结论：Molnupiravir是预防严重COVID-19和住院的有效疗法。
